« Return to News | Drug Sponsors | R&D Trends

Pfizer cuts 15 R&D projects, buys King

Wednesday, March 2, 2011 12:56 PM

Pfizer has cut its R&D pipeline again, removing 15 experimental projects in a bid to restructure its operations and conserve earnings, according to PharmaTimes. 

Projects being eliminated span early- to late-stage trials, including Lyrica (pregabalin) for generalized anxiety disorder. Three phase III projects were cut: apixaban for acute coronary syndrome, Thelin (sitaxentan) for pulmonary arterial hypertension and Lyrica (pregabalin) for post-operative pain. These cuts follow an earlier cut of its R&D pipeline last year, when Pfizer said no less than 31 projects had to end to help it leverage its best assets and maximize efficiency.

Pfizer also announced the completion of its $3.6 billion purchase of King Pharmaceuticals. The deal provides access to King’s Meridian auto-injector business for emergency drug delivery, which develops and manufactures the EpiPen, as well as its Alpharma animal health business.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

December 17

Medici Global says its Alzheimer's Facebook page demonstrates the need for more early detection trials

Analysts: Expect more equity purchases of CROs in 2013

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

January 2013

Parexel celebrates 30 years of change, growth
CRO's founder and chairman reflects on challenges of the past, present and future

Strategies for increasing patient diversity in trials
Sponsors look to improve racial, ethnic recruitment without going overseas

Already a subscriber?
Log in to your digital subscription.

Purchase the January issue.

Subscribe to The CenterWatch Monthly.

December 2012

Publicity, regulation tightening reins on use of KOLs
Debate rages over need to revamp how sponsors use, pay medical experts

Time may be right to makeover the investigator brochure
Size, complexity prevent critical document from being thoroughly read

Already a subscriber?
Log in to your digital subscription.

Purchase the December issue.

Subscribe to The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.